ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Publishes Two Guidances for Lab-Developed Tests

October 3, 2014

ASCO Recommends Discussing Pharmacological Prevention

July 26, 2013

In Brief: James Downing named CEO of St. Jude

June 27, 2014

Dingell Subcommittee Report Next Month To Include New Info

July 1, 1994

The Cancer Letter Wins Journalism Award

April 1, 2011

FDA Approves Velcade For Treatment Of Refractory Multiple Myeloma

May 30, 2003